JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB126763

Anti-CXCL5 antibody [EPR4450(2)]

  • 20ul selling size
  • KO Validated
  • RabMAb
  • Recombinant
  • What is this?

Be the first to review this product! Submit a review

|

(9 Publications)

Knockout Tested Rabbit Recombinant Monoclonal CXCL5 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 9 publications.

View Alternative Names

ENA78, SCYB5, CXCL5, C-X-C motif chemokine 5, ENA-78(1-78), Epithelial-derived neutrophil-activating protein 78, Neutrophil-activating peptide ENA-78, Small-inducible cytokine B5

4 Images
Immunoprecipitation - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)
  • IP

Lab

Immunoprecipitation - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)

CXCL5 was immunoprecipitated from 0.35 mg A549 (Human lung carcinoma epithelial cell) whole cell lysate 10 μg with 126763 at 1/50 dilution (2μg). VeriBlot for IP Detection Reagent (HRP) (ab131366) was used at 1/5000 dilution.

Lane 1 : A549 (Human lung carcinoma epithelial cell) whole cell lysate 10 μg

Lane 2 : ab126763 IP in A549 whole cell lysate

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab126763 in A549 whole cell lysate

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

All lanes:

Immunoprecipitation - Anti-CXCL5 antibody [EPR4450(2)] (ab126763)

Predicted band size: 12 kDa

Observed band size: 12 kDa

false

Western blot - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)
  • WB

Unknown

Western blot - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)

All lanes:

Western blot - Anti-CXCL5 antibody [EPR4450(2)] (ab126763) at 1/1000 dilution

Lane 1:

A549 cell lysate, treated with TNF alpha and TPA at 10 µg

Lane 2:

A549 cell lysate, untreated at 10 µg

Lane 3:

Human CXCL5 recombinant protein at 0.001 µg

Secondary

All lanes:

Goat anti-Rabbit HRP at 1/2000 dilution

Predicted band size: 12 kDa

false

Western blot - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)
  • WB

Supplier Data

Western blot - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)

False colour image of Western blot : Anti-CXCL5 antibody [EPR4450(2)] staining at 1/1000 dilution, shown in green; Mouse anti-GAPDH antibody [6C5] (ab8245) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab126763 was shown to bind specifically to CXCL5. A band was observed at 7 kDa in treated wild-type A549 cell lysates with no signal observed at this size in CXCL5 knockout cell line ab275838 (knockout cell lysate ab275812). To generate this image, wild-type and CXCL5 knockout A549 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-CXCL5 antibody [EPR4450(2)] (ab126763) at 1/1000 dilution

Lane 1:

Wild-type A549 Untreated Control cell lysate at 20 µg

Lane 2:

Wild-type A549 Treated TNFa (10 ng/mL, 24 h) + PMA (10 nM, 24 h) cell lysate at 20 µg

Lane 3:

CXCL5 knockout A549 Untreated Control cell lysate at 20 µg

Lane 4:

CXCL5 knockout A549 Treated TNFa (10 ng/mL, 24 h) + PMA (10 nM, 24 h) cell lysate at 20 µg

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Predicted band size: 12 kDa

Observed band size: 7 kDa

false

OI-RD Scanning - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)
  • OI-RD Scanning

Unknown

OI-RD Scanning - Anti-CXCL5 antibody [EPR4450(2)] (AB126763)

We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody. Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

  • Carrier free

    Anti-CXCL5 antibody [EPR4450(2)] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR4450(2)

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IP, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/100 - 1/500", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" } } }

Product details

Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please contact us for more information.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Storage information
Stable for 12 months at -20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CXCL5 also known as LIX (Liposaccharide-induced CXC chemokine) is a small cytokine belonging to the CXC chemokine family. It plays a significant role in immunological responses by acting as a chemoattractant for neutrophils. CXCL5 has a molecular mass of around 12 kDa. The protein is mainly expressed in neutrophils epithelial cells and endothelial cells. It is often studied alongside its competitors in different therapeutic and diagnostic contexts.
Biological function summary

CXCL5 affects inflammation and the immune response by modulating neutrophil recruitment to sites of infection or injury. It is a part of the larger network of chemokines that direct leukocyte movement throughout the body. While CXCL5 does not form a complex in a traditional sense it does interact dynamically with CXCR2 receptor to exert its effects. These interactions are pivotal to the protein’s role in orchestrating the immune system’s response to diverse stimuli.

Pathways

CXCL5 plays a part in the chemokine signaling pathway and the inflammatory response pathway. These pathways are important in mediating immune surveillance and inflammation. CXCL5 through these pathways has a strong connection to other CXC family proteins like CXCL1 and the receptor CXCR2 which allows for a coordinated response during immune challenges and recovery processes.

CXCL5 is relevant in the context of chronic inflammatory disorders such as rheumatoid arthritis and cancer specifically its role in tumor-related inflammation. In these conditions CXCL5 is linked to the exacerbation of inflammatory states and promotion of tumor growth via angiogenesis. The protein's interactions with CXCR2 play a significant role in these disease processes representing potential therapeutic targets for managing inflammation and modulating cancer progression.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Involved in neutrophil activation. In vitro, ENA-78(8-78) and ENA-78(9-78) show a threefold higher chemotactic activity for neutrophil granulocytes.
See full target information CXCL5

Publications (9)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 16:1548635 PubMed40313933

2025

TGFB1/CXCL5 axis regulation by LCN2 overexpression: a promising strategy to inhibit colorectal cancer metastasis and enhance prognosis.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaotian Song,Shuai Xu,Dan Song,Juan Wang,Bin Bai,Yanxin An,Bin Yang,Shiqi Wang,Qingchuan Zhao,Pengfei Yu

Antioxidants (Basel, Switzerland) 13: PubMed39765818

2025

The C-X-C Motif Chemokine Ligand 5, Which Exerts an Antioxidant Role by Inducing HO-1 Expression, Is C-X-C Motif Chemokine Receptor 2-Dependent in Human Prostate Stroma and Cancer Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Kang-Shuo Chang,Syue-Ting Chen,Shu-Yuan Hsu,Hsin-Ching Sung,Wei-Yin Lin,Ke-Hung Tsui,Yu-Hsiang Lin,Chen-Pang Hou,Horng-Heng Juang

Cell discovery 10:109 PubMed39468013

2024

Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Yohei Saito,Yi Xiao,Jun Yao,Yunhai Li,Wendao Liu,Arseniy E Yuzhalin,Yueh-Ming Shyu,Hongzhong Li,Xiangliang Yuan,Ping Li,Qingling Zhang,Ziyi Li,Yongkun Wei,Xuedong Yin,Jun Zhao,Seyed M Kariminia,Yao-Chung Wu,Jinyang Wang,Jun Yang,Weiya Xia,Yutong Sun,Eek-Hoon Jho,Paul J Chiao,Rosa F Hwang,Haoqiang Ying,Huamin Wang,Zhongming Zhao,Anirban Maitra,Mien-Chie Hung,Ronald A DePinho,Dihua Yu

Nature communications 13:7796 PubMed36528626

2022

Translation factor eIF5a is essential for IFNγ production and cell cycle regulation in primary CD8 T lymphocytes.

Applications

Unspecified application

Species

Unspecified reactive species

Thomas C J Tan,Van Kelly,Xiaoyan Zou,David Wright,Tony Ly,Rose Zamoyska

Analytical cellular pathology (Amsterdam) 2022:5418356 PubMed35936390

2022

miR-145-3p Hampers the Malignant Progression of Esophageal Carcinoma via CXCL5 Downregulation.

Applications

Unspecified application

Species

Unspecified reactive species

Gang Chen,Zhihua Teng,Zhouyu Zhu,Xing Li

Cell death discovery 8:243 PubMed35504887

2022

circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5.

Applications

Unspecified application

Species

Unspecified reactive species

Qun Lu,Haoli Yin,Yongming Deng,Wei Chen,Wenli Diao,Meng Ding,Wenmin Cao,Yao Fu,Wenjing Mo,Xiaoqing Chen,Qing Zhang,Xiaozhi Zhao,Hongqian Guo

Human vaccines & immunotherapeutics 18:2065837 PubMed35486941

2022

MicroRNA-873-5p suppresses cell malignant behaviors of thyroid cancer via targeting CXCL5 and regulating P53 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Wang Chang,Qing Chang,Haodong Lu,Shiguang Liu,Yanbing Li,Chunyou Chen

Experimental and therapeutic medicine 21:301 PubMed33717244

2021

MicroRNA-432-5p inhibits cell migration and invasion by targeting CXCL5 in colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Man Luo,Zuowei Hu,Yuefeng Kong,Lingyi Li

Microbiology and immunology 65:40-47 PubMed33026667

2021

CXC chemokine ligand 5 (CXCL5) disrupted the permeability of human brain microvascular endothelial cells via regulating p38 signal.

Applications

Unspecified application

Species

Unspecified reactive species

Min Yu,Xiaokun Ma,Dudu Jiang,Lijing Wang,Qing Zhan,Jiangmin Zhao
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com